Lightnews — Scholar-powered news

MIMETAS @mimetas.bsky.social · 4d

Our Early Stage Researcher Tomás Coimbra is at FIGON Dutch Medicines Days (Oct 8–9)! ✨

He’s presenting:
“A scalable human primary liver model to study cell-cell interactions.”
📍 Poster sessions: 12:30–14:00, both days.
Don’t miss it if you’re attending!

MIMETAS @mimetas.bsky.social · 5d

In this customer publication, researchers used MIMETAS’ OrganoReady® Colon Organoid and OrganoTEER® to show how a Lactobacillaceae-derived postbiotic protects the gut barrier, supports recovery, and reduces inflammation. Read it here: www.mdpi.com/2304-8158/14...

www.mdpi.com

MIMETAS @mimetas.bsky.social · 13d

GI toxicity is a major side effect of cancer therapies. Our 3D Colon Organoid Model brings human relevance + high-throughput screening to better predict drug-induced GI toxicity. Explore our poster 👉 shorturl.at/8APaR #Toxicology #Organoids #DrugDevelopment #Innovation

MIMETAS @mimetas.bsky.social · 17d

📸 Proud moment! Our VP of Biology, Henriette Lanz, presented at #GoodbyeFlatBiology. She shared insight on using patient-derived 3D tumor models to support cell therapy programs by replicating the complex tumor-microenvironment in vitro.

#OrgansOnChips #FutureOfBiology

1

MIMETAS @mimetas.bsky.social · 18d

🔬Today on #WorldCancerResearchDay, we recognize the need for research that leads to better cancer treatments and outcomes.

At MIMETAS, we support scientists with human relevant 3D models that improve translation from lab to clinic.

MIMETAS @mimetas.bsky.social · 26d

🚨 #EuroTox Day 2! Meet MIMETAS’ Brian Duggan & Debarati Shome as they present two posters on Risk Prediction and Assessment using NAMs and An Assay-Ready ASC-Derived Colon Organoid Model for Evaluating Therapy-Induced Gastrointestinal Toxicity. Join the sessions or connect with our experts!

1

MIMETAS @mimetas.bsky.social · Sep 12

📢 New customer publication! Researchers used our OrganoPlate® platform to develop a Glomerulus-on-a-Chip to show vincristine protects podocytes in FSGS, a major kidney disease. First evidence of its protective effect! Read the publication: www.sciencedirect.com/science/arti...

1

MIMETAS @mimetas.bsky.social · Sep 10

Meet MIMETAS at #EUROTOX2025 in Athens, Sept 14–17! Connect with our experts Debarati Shome & Brian Duggan to explore our latest 3D human tissue models for toxicity research. Don’t miss our posters on Sept 15 & 16! 🔗 eurotox2025.com #Toxicology #DrugSafety

3

MIMETAS @mimetas.bsky.social · Sep 10

Team spirit on the canals! 🚤 Our MIMETAS crew competed in a boating challenge through Leiden, celebrated the winners 🏆, and wrapped it up with a cozy dinner together for our annual company outing. A day of laughter, teamwork & connection!

MIMETAS @mimetas.bsky.social · Sep 4

At MIMETAS, growth is personal. Marketing Specialist Chiwan Chiang shares how curiosity, creativity, and stepping outside your comfort zone shape a career—and a company.

💬 “When you think you have failed, you’ve only gained knowledge.”

Full interview: shorturl.at/hBbyY

MIMETAS @mimetas.bsky.social · Sep 2

How do you model lungs more realistically? 🌬️ Find out in our Sept 9 webinar. Register: shorturl.at/8Es4r #OrganonaChip #LungResearch #LungModels

MIMETAS @mimetas.bsky.social · Aug 27

🧠 New study from MIMETAS & Roche (pRED) shows how the ApoE4 Alzheimer’s risk gene alters brain endothelial function & iron transport.

Using our iPSC-based BBB model + Roche’s BrainShuttle tech, we uncovered ApoE4-driven changes that may shape how therapies can reach the brain. shorturl.at/RwgUP

1

MIMETAS @mimetas.bsky.social · Aug 21

In this app note, read about a high-throughput 3D human BBB model that has:
🔹 Human-relevant barrier physiology
🔹 Tight junctions & transporter expression
🔹 Predictable response to compounds
🔹 High-throughput with 40–64 perfused chips
shorturl.at/ire7v

MIMETAS @mimetas.bsky.social · Aug 19

In our latest The ‘I’ in MIMETAS feature, Product Design Engineer Frederik Schavemaker shares how intuition, curiosity, and design come together to bring tools like OrganoTEER® to life.

👉 Meet the people behind the biology: shorturl.at/yUp6q

#TheIinMIMETAS #ProductDesign #OrganOnChip

MIMETAS @mimetas.bsky.social · Aug 13

MIMETAS' Oncology Services help pharma accelerate cancer drug discovery with 3D tumor models that truly mimic human biology. From CAR T cell assays to large-scale screening, we deliver predictive insights for faster, targeted therapies.

🔗 Explore: shorturl.at/fnWTA
#Oncology #DrugDiscovery

MIMETAS @mimetas.bsky.social · Aug 11

Many immune diseases lack effective treatments. In this webinar, learn how how 3D disease models can improve drug discovery for inflammation & IBD and improve pre-clinical predictability for immune-targeting therapies.

Watch now: shorturl.at/BZygd
#InflammationResearch

MIMETAS @mimetas.bsky.social · Aug 7

Modeling pulmonary fibrosis in vitro remains a challenge due to limited physiological relevance in traditional systems. Our Airway-on-a-Chip (AoC) model offers a more representative approach.

📄 Explore this application in the full poster: shorturl.at/3DgUG

MIMETAS @mimetas.bsky.social · Aug 4

The first large-scale phenotypic screen using Organ-on-a-Chip: MIMETAS scientists grew 4,000 perfused micro-vessels and screened 1,537 protein kinase inhibitors.

They identified 53 compounds with anti-angiogenic activity - 44 of them previously unknown. shorturl.at/NbSfU

MIMETAS @mimetas.bsky.social · Jul 30

💬 “You know far less than you think. Stay humble, stay curious.” – Lenie van den Broek, Director Biology Discovery @ MIMETAS

From partnership collabs to lung model breakthroughs, Lenie’s story is all heart + science.

👉 Read her full interview: shorturl.at/0RWW9

MIMETAS @mimetas.bsky.social · Jul 25

In this whitepaper, explore how human 3D tissue models are transforming immunology drug discovery - boosting accuracy, insights & efficacy.

🔬 Covers IBD, CKD, vascular inflammation
📊 Real-world case studies
📥 Read it here: shorturl.at/41A0a
#Immunology #DrugDiscovery #OrganOnAChip #IBD #CKD

MIMETAS @mimetas.bsky.social · Jul 23

Together with sanofi, we developed a human immunocompetent kidney-on-a-chip model to study renal inflammation. This tri-culture system enables immune cell migration tracking & drug testing in a 3D flow environment.
📖 Read more: shorturl.at/z1SEe
#OrganOnChip #CKD

2

MIMETAS @mimetas.bsky.social · Jul 21

☀️ Team, Sunshine & BBQ at MIMETAS!

Great food, even better people! Our summer BBQ was all about good vibes, teamwork, and celebrating the amazing crew that makes MIMETAS what it is. Thanks to everyone who joined, grilled, and brought the energy!

MIMETAS @mimetas.bsky.social · Jul 14

How can 3D human in vitro models improve drug safety testing?

🎥Watch our on-demand webinar on current and future opportunities for microphysiological systems in toxicity testing. register.gotowebinar.com/register/882...
#DrugSafety #Toxicology #3DCellCulture #Webinar

MIMETAS @mimetas.bsky.social · Jul 10

The NIH will no longer fund research proposals based solely on animal models - a major shift in how we approach early-stage drug development.

At MIMETAS, we help our clients develop treatments faster with predictive, human-relevant Organ-on-a-Chip solutions. shorturl.at/H77TX

NIH announces end to funding for animal-only studies - Drug Discovery and Development

Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.

www.drugdiscoverytrends.com

MIMETAS @mimetas.bsky.social · Jul 8

🎉 We joined the unveiling of Ombion – the new name for the Centre for Animal-Free Biomedical Translation!

MIMETAS is proud to be part of this €245M initiative driving human-relevant science. Our 3D human tissue models support safer, animal-free innovation in ALS, back pain & food allergy.

1